Novo Nordisk says real-world analysis links Ozempic 2 mg to 6% lower MACE risk vs switching to Lilly’s Mounjaro in type 2 diabetes

PUBT · 1d ago
Novo Nordisk says real-world analysis links Ozempic 2 mg to 6% lower MACE risk vs switching to Lilly’s Mounjaro in type 2 diabetes
  • Novo Nordisk reported a real-world analysis finding lower cardiovascular risk when patients raised Ozempic to 2 mg versus switching to Mounjaro.
  • Results were presented at the EASD Annual Meeting 2026 in Milan.
  • Study tracked adults with type 2 diabetes already using semaglutide 1 mg, reflecting common treatment intensification decisions in practice.
  • Findings support dose escalation as a competitive positioning point against tirzepatide in cardiovascular outcomes for established semaglutide users.
  • Safety outcomes were not evaluated in the analysis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.